S&P 500 7,500.58 ▲ 80.48 (+1.08%) DOW 51,564.70 ▲ 72.10 (+0.14%) NASDAQ 26,517.93 ▲ 496.23 (+1.91%) US Markets Closed â€ĸ 06:44 AM ET

ERNAW

Ernexa Therapeutics Inc.

Price Chart
Latest Quote

$0.06

-0.02 (-23.85%)
Current Price
Previous Close $0.08
Open $0.06
Day High $0.08
Day Low $0.06
Volume 51,481
Fetched: 2026-06-22T10:44:06
Stock Information
Total Debt $389K
Cash Equivalents $9.18M
Net Income $-11.40M
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Income$-11.40M
Book/sh$5.88
Employees5
Financial Ratios
Quick Ratio2.68
Current Ratio2.89
Debt/Eq5.67
Returns & Margins
ROA-81.20%
ROE-2505.61%
Ownership
Insider & Institutional transactions data not available
Valuation Ratios
P/B0.01
Analyst Data
Recommendationnone
Technical Indicators
Shares Float818K
Performance History
YTD+0.00%
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-18 $0.06 51,481
About Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.